VAL-083: An Important Biological Approach to Fighting Drug-Resistant Tumors
Demonstrating Potency in Clinical Trials
DelMar Pharmaceuticals’ lead compound, VAL-083, has been evaluated in more than 40 Phase 1 and Phase 2 clinical trials by the U.S. National Cancer Institute and was found to have anti-cancer activities against various cancers, including brain tumors and ovarian cancers.
|Other||Pre-clinical||Phase 1||Phase 2||Phase 3||NDA|
|Single Agent: Recurrent TMZ-resistant (MDACC)MGMT-unmethylated GBM||Pre-clinical Phase complete||Phase 1 Phase complete||Phase 2 Phase in progress||Phase 3 Phase not started||NDA Phase not started|
|Combination with XRT: Newly Diagnosed (Sun Yat-sen University)MGMT-unmethylated GBM||Pre-clinical Phase complete||Phase 1 Phase complete||Phase 2 Phase in progress||Phase 3 Phase not started||NDA Phase not started|
|Ovarian cancer||Pre-clinical Phase in progress||Phase 1 Phase not started||Phase 2 Phase not started||Phase 3 Phase not started||NDA Phase not started|
|Pediatric Brain Tumor||Pre-clinical Phase in progress||Phase 1 Phase not started||Phase 2 Phase not started||Phase 3 Phase not started||NDA Phase not started|
Glioblastoma Multiforme (GBM) is the most common and lethal form of brain cancer. As a unique small molecule therapeutic, VAL-083 can potentially offer a new paradigm in the treatment of GBM.
Our research supports VAL-083’s potential as a new therapeutic option for platinum-resistant ovarian cancer patients whose treatment is underserved by currently available therapy.
Pediatric Brain Tumors
Children with high grade glioma have very limited treatment options. VAL-083 has demonstrated promising activities in the treatment of pediatric brain tumors in NCI clinical trials and our recent preclinical studies, supporting future clinical evaluation.
Our Platform Strategy: Unleashing the Potential of Biology
Our drug development strategy is built on a robust understanding of cancer biology. We use modern scientific approaches to determine where we can solve problems for specific tumor types.
Our team is identifying opportunities where a modernized understanding of the anti-cancer mechanism of VAL-083 suggests that this agent can address an unmet need. By showing that VAL-083 is active where others fail, we can demonstrate that our therapies may have the ability to improve patient survival and quality of life.
Explore Our Scientific Publications & Presentations
Dive deeper into our work by reviewing our robust catalog of scientific publications and presentations.
View Publications and Presentations